| 0.9325 0.001 (0.05%) | 07-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.16 | 1-year : | 1.24 |
| Resists | First : | 0.99 | Second : | 1.07 |
| Pivot price | 0.94  |
|||
| Supports | First : | 0.87 | Second : | 0.73 |
| MAs | MA(5) : | 0.93 |
MA(20) : | 0.94 |
| MA(100) : | 1.05 |
MA(250) : | 1.09 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.5 |
D(3) : | 41.6 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 2.5 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ELUT ] has closed above bottom band by 33.3%. Bollinger Bands are 62.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.95 - 0.96 | 0.96 - 0.96 |
| Low: | 0.9 - 0.91 | 0.91 - 0.91 |
| Close: | 0.92 - 0.93 | 0.93 - 0.94 |
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
Sat, 18 Jul 2026
Lake Street Reaffirms Their Buy Rating on Elutia (ELUT) - The Globe and Mail
Fri, 17 Jul 2026
Elutia Sheds Legacy Business to Chase $1.5 Billion Market Opportunity - Benzinga
Thu, 16 Jul 2026
Elutia Agrees to Sell SimpliDerm for Up to $11 Million - marketscreener.com
Thu, 16 Jul 2026
Elutia to sell SimpliDerm business for up to $11 million - Investing.com
Thu, 16 Jul 2026
Elutia (ELUT) Finalizes Sale of SimpliDerm Business for Up to $1 - GuruFocus
Thu, 16 Jul 2026
Elutia Targets Breast Cancer Surgery Where Complications Reach 1 in 3 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 45.6 (%) |
| Shares Short | 53 (K) |
| Shares Short P.Month | 43 (K) |
| EPS | -0.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.5 |
| Profit Margin | 400.1 % |
| Operating Margin | -184.4 % |
| Return on Assets (ttm) | -26.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 5.5 % |
| Gross Profit (p.s.) | 0.15 |
| Sales Per Share | 0.28 |
| EBITDA (p.s.) | -0.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -1.44 |
| PEG Ratio | 0 |
| Price to Book value | 1.82 |
| Price to Sales | 3.3 |
| Price to Cash Flow | -0.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|